Pharmacology and Treatment
Interferon Alpha as Adjuvant Postsurgical Treatment of Melanoma: A Meta-AnalysisPirard D.a · Heenen M.a · Melot C.b · Vereecken P.a
aDepartment of Dermatology and bIntensive Care, Erasme Hospital, Brussels, Belgium
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Background: The literature on the benefit of α-interferon (IFN-α) as adjuvant postsurgical treatment of melanoma reports discordant results. Objective: With the published data so far, we performed a meta-analysis in order to evaluate the effect of IFN-α on the relapse rate (RR) and the overall survival (OS). Methods: Published randomised trials were identified by Medline search. Stage IV melanoma was not considered. Results: Nine published studies were included, with a total of 2,880 patients. Both the per protocol and the intention-to-treat analysis show that IFN-α significantly decreased the RR (OR = 0.74; 95% CI = 0.64–0.86). Subgroup analyses show that, for all stages, high and low doses decreased the RR (OR = 0.71, 95% CI = 0.54–0.92, and OR = 0.76, 95% CI = 0.63–0.91, respectively). No difference has been evidenced on OS. Conclusions: High and low doses of IFN-α significantly decrease the RR, but the OS does not seem to be improved.
© 2004 S. Karger AG, Basel
- Rigel DS, Carucci JA: Malignant melanoma: Prevention, early detection and treatment in the 21st century. CA Cancer J Clin 2000;50:215–236.
- Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH: Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group trial EST 1684. J Clin Oncol 1996;14:7–17.
- Grob JJ, Deno B, De la Salmonière P, Delaunay M, Cupissol D, Guillot B, Souteyrand P, Sassolas B, Cesarini JP, Lionnet S, Lok C, Chastang C, Bonerandi JJ: Randomised trial of interferon α-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastasis. Lancet 1998;351:109–110.
Kleeberg U, Bröcker EB, Lejeune F, Chartier C, Egger C, Marsden J, Ruiter D, Suciu S: Adjuvant trial in melanoma patients comparing rIFN-α to IFN-γ to Iscador to a control group after curative resection of high risk primary (>3 mm) or regional lymph node metastasis (EORTC 18871) (abstract 264). Eur J Cancer 1999;suppl 4:S82.
Krajsova I, Kysela T, Horazdovsky J, Kohoutek M: High risk cutaneous melanoma: Impact of the adjuvant interferon alpha 2 treatment (abstract 2901). ASCO, San Francisco, 2001.
Hancock BW, Wheatley K, Harrison G, Gorc M: Aim high – Adjuvant interferon in melanoma (high risk), a United Kingdom Co-Ordinating Committee on Cancer Research (UKCCCR) randomised study of observation versus adjuvant low dose extended duration interferon alpha-2a in high risk resected malignant melanoma (abstract 1393). ASCO, San Francisco, 2001.
Cucherat M: Méta-analyse des essais thérapeutiques. Paris, Masson, 1997, pp 149–203.
- Kirkwood JM, Ibrahim JG, Sondak VK, et al: High-and-low dose interferon alfa-2b in high-risk melanoma: First analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000;18:2444–2458.
- Rusciani L, Petraglia S, Alotto M, Calvieri S, Vezzoni G: Postsurgical adjuvant therapy for melanoma. Cancer 1997;79:2354–2360.
- Creagan ET, Dalton RJ, Ahmann DL, et al: Randomised, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. J Clin Oncol 1995;13:2776–2783.
- Pehamberger H, Soyer PH, Steiner A, et al: Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. J Clin Oncol 1998;16:1425–1429.
- Cameron DA, Cornbleet MC, Mackie RM, et al: Adjuvant interferon alpha 2-b in high risk melanoma – The Scottish study. Br J Cancer 2001;84:1146–1149.
- Kokoschka E-M, Trautinger F, Knobler RM, Pohl-Markl H, Micksche M: Long-term adjuvant therapy of high risk malignant melanoma with interferon α2b. J Invest Dermatol 1990;95:193S–197S.
- Cascinelli N, Belli F, Mackie RM, Santinami M, Bufalino R, Morabito A: Effect of long term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: A randomised trial. Lancet 2001;358:866–869.
- Hillner BE, Kirkwood JM, Atkins MB, Johnson ER, Smith TJ: Economic analysis of adjuvant interferon alfa-2b in high risk melanoma based on projections from eastern cooperative oncology group 1684. J Clin Oncol 1997;15:2351–2358.
Saiag P: Interféron à hautes doses et traitement adjuvant du mélanome de mauvais pronostic: requiem pour une AMM? Ann Dermatol Vénéréol 1999;126:211–213.
- Kimyai-Asadi A, Usman A: The use of interferon alfa as adjuvant therapy for advanced cutaneous melanoma: The need for more evidence. J Am Acad Dermatol 2000;43:708–711.
Essner R: The role of lymphoscintigraphy and sentinel node mapping in assessing patient risk in melanoma. Semin Oncol 1997;24(suppl 4):S8–S10.
- Balch CM, Buzaïd A, Soong SJ, et al: Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001;19:3635–3648.
- Lens MB, Dawes M: Interferon alfa therapy for malignant melanoma: A systematic review of randomised controlled trials. J Clin Oncol 2002;20:1818–1825.
Wheatley K, Hancock B, Gore M, Suciu S, Eggermont A: Interferon-α as adjuvant therapy for melanoma: A meta-analysis of the randomised trials (abstract 1394). ASCO, San Francisco, 2001.
- Kanzler MH, Swetter SM: Malignant melanoma. J Am Acad Dermatol 2003;48:780–783.
- Sondak VK: Use of adjuvant therapy in cutaneous melanoma. Expert Rev Anticancer Ther 2001;1:421–426.
- Dummer R, Bosch U, Panizzon R, Bloch PH, Burg G: Swiss guidelines for the treatment and follow-up of cutaneous melanoma. Dermatology 2001;203:75–80.
- Roberts DL, Anstey AV, Bartow RJ, Cox NH, Newton Bishop JA, Corrie PG, Evans J, Gire ME, Hall PN, Kirkham N: UK guidelines for the management of cutaneous melanoma. Br J Dermatol. 2002;146:7–17.
- Brochez L, Verhaeghe E, Sales F, Del Marmol V, Deraemaecker R, Vossaert K, Naeyaert JM: Current guidelines in melanoma treatment. Melanoma Working Group of Gent and Bordet. Dermatology 2000;200:160–166.
- Kroon BB, Bergman W, Coebergh JW, Ruiter DJ: Consensus on the management of malignant melanoma of the skin in the Netherlands. Melanoma Res 1999;9:207–212.
- Negries S, Fervers B, Bailly C, Beckendorf V, Cupissol D, Dore JF, Dorval T, Garbay JR, Vilmer C: Standards, options and recommendations (SOR): Clinical practice guidelines for diagnosis, treatment and follow-up of cutaneous melanoma. Bull Cancer 2000;87:173–182.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.